Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer - Université Paris-Est-Créteil-Val-de-Marne Access content directly
Journal Articles Cancer Medicine Year : 2020

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer

Régine Lamy
  • Function : Author
Jean‐louis Bizec
  • Function : Author
Karim Amrane

Abstract

Background: A standard of care for pretreated, advanced non-small-cell lung cancers (NSCLCs), nivolumab has demonstrated long-term benefit when administered for 2 years. We aimed to better discern an optimized administration duration by retrospectively analyzing real-life long-term efficacy in a prospective cohort. Methods: All nivolumab-treated adults with advanced NSCLCs (01/09/2015 to This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Fichier principal
Vignette du fichier
CAM4-9-6923.pdf (473.46 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04143364 , version 1 (27-06-2023)

Identifiers

Cite

Margaux Geier, Renaud Descourt, Romain Corre, Guillaume Léveiller, Régine Lamy, et al.. Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer. Cancer Medicine, 2020, 9 (19), pp.6923-6932. ⟨10.1002/cam4.3120⟩. ⟨hal-04143364⟩
9 View
11 Download

Altmetric

Share

Gmail Facebook X LinkedIn More